Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients

被引：8

作者：

Qu, Lihui ^{[1
,2
,3
,4
]}

Lu, Yingying ^{[1
,2
,3
,4
]}

Ying, Meike ^{[1
,2
,3
,4
]}

Li, Bingjue ^{[1
,2
,3
,4
]}

Weng, Chunhua ^{[1
,2
,3
,4
]}

Xie, Zhoutao ^{[1
,2
,3
,4
]}

Liang, Ludan ^{[1
,2
,3
,4
]}

Lin, Chuan ^{[1
,2
,3
,4
]}

Yang, Xian ^{[1
,2
,3
,4
]}

Feng, Shi ^{[1
,2
,3
,4
]}

Wang, Yucheng ^{[1
,2
,3
,4
]}

Shen, Xiujin ^{[1
,2
,3
,4
]}

Zhou, Qin ^{[1
,2
,3
,4
]}

Chen, Ying ^{[1
,2
,3
,4
]}

Chen, Zhimin ^{[1
,2
,3
,4
]}

Wu, Jianyong ^{[1
,2
,3
,4
]}

Lin, Weiqiang ^{[1
,2
,3
,4
,9
]}

Shen, Yi ^{[8
]}

Qin, Jing ^{[5
,7
]}

Xu, Hang ^{[5
]}

Xu, Feng ^{[5
,7
]}

Wang, Junwen ^{[6
,8
]}

Chen, Jianghua ^{[1
,2
,3
,4
]}

Jiang, Hong ^{[1
,2
,3
,4
]}

Huang, Hongfeng ^{[1
,2
,3
,4
]}

机构：

[1] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Kidney Dis Ctr, Hangzhou, Zhejiang, Peoples R China

[2] State Adm Tradit Chinese Med PR China, Kidney Dis Immunol Lab, Grade Lab 3, Hangzhou, Zhejiang, Peoples R China

[3] Minist Hlth, Key Lab Multiple Organ Transplantat, Hangzhou, Zhejiang, Peoples R China

[4] Key Lab Nephropathy, Hangzhou, Zhejiang, Peoples R China

[5] Univ Hong Kong, LKS Fac Med, Dept Biochem, Hong Kong, Hong Kong, Peoples R China

[6] Univ Hong Kong, LKS Fac Med, Ctr Genom Sci, Hong Kong, Hong Kong, Peoples R China

[7] Univ Hong Kong, Shenzhen Inst Res & Innovat, Shenzhen, Guangdong, Peoples R China

[8] Zhejiang Univ, Dept Epidemiol, Coll Med, Hangzhou, Zhejiang, Peoples R China

[9] Zhejiang Univ, Inst Translat Med, Coll Med, Hangzhou, Zhejiang, Peoples R China

来源：

ONCOTARGET | 2017年 / 8卷 / 46期

关键词：

CYP3A5; FK506; renal transplantation; acute rejection; KIDNEY-TRANSPLANTATION; ACUTE REJECTION; RECIPIENTS; PHARMACOKINETICS; CYCLOSPORINE; POLYMORPHISM; IMPACT; IMMUNOSUPPRESSION; OUTCOMES; DOSAGE;

D O I：

10.18632/oncotarget.18150

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tacrolimus (FK506) and cyclosporine A (CsA) are widely used to protect graft function after renal transplantation. The aim of the present study is to determine whether the single nucleotide polymorphism of CYP3A5 is a predictive index of FK506 dose requirement, and also the selection yardstick of FK506 or CsA treatment. We tested archival peripheral blood of 218 kidney recipients for CYP3A5 genotyping with PCR-SSP. Meanwhile, the dose of FK506 and CsA was recorded, blood concentration of the drugs was measured, and graft outcome was monitored. These results indicate that CYP3A5*AA/AG carriers need higher FK506 dose than CYP3A5*GG homozygote to achieve the target blood concentration. For CYP3A5*GG carriers, taking FK506 or CsA are both advisable. CYP3A5*AA/AG carriers preferred to CsA treatment depending on the graft outcomes and drug costs. CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients.

引用

页码：81285 / 81294

页数：10

共 20 条

[1] Racial variation in dosage requirements of tacrolimus [J].

Andrews, PA ;

Sen, M ;

Chang, RWS .

LANCET, 1996, 348 (9039) :1446-1446

[2] C4d as a significant predictor for humoral rejection in renal allografts [J].

Chen, JH ;

Xie, WQ ;

Wang, HP ;

Jin, J ;

Wu, JY ;

He, Q .

CLINICAL TRANSPLANTATION, 2005, 19 (06) :785-791

[3]

Chen Jianghua, 2005, Clin Transpl, P209

[4] Identification and functional characterization of eight CYP3A4 protein variants [J].

Eiselt, R ;

Domanski, TL ;

Zibat, A ;

Mueller, R ;

Presecan-Siedel, E ;

Hustert, E ;

Zanger, UM ;

Brockmoller, J ;

Klenk, HP ;

Meyer, UA ;

Khan, KK ;

He, YA ;

Halpert, JR ;

Wojnowski, L .

PHARMACOGENETICS, 2001, 11 (05) :447-458

[5] The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring [J].

Felipe, CR ;

Silva, HT ;

Machado, PG ;

Garcia, R ;

Moreira, SRD ;

Pestana, JO .

CLINICAL TRANSPLANTATION, 2002, 16 (04) :262-272

[6] Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation [J].

Gervasini, Guillermo ;

Garcia, Montserrat ;

Maria Macias, Rosa ;

Jose Cubero, Juan ;

Caravaca, Francisco ;

Benitez, Julio .

TRANSPLANT INTERNATIONAL, 2012, 25 (04) :471-480

[7] Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine plus mycophenolate mofetill after cadaveric kidney transplantation: Results at three years. [J].

Gonwa, T ;

Johnson, C ;

Ahsan, N ;

Alfrey, EJ ;

Halloran, P ;

Stegall, M ;

Hardy, M ;

Metzger, R ;

Shield, C ;

Rocher, L ;

Scandling, J ;

Sorensen, J ;

Mulloy, L ;

Light, J ;

Corwin, C ;

Danovitch, G ;

Wachs, M ;

VanVeldhuisen, P ;

Leonhardt, M ;

Fitzsimmons, WE .

TRANSPLANTATION, 2003, 75 (12) :2048-2053

[8] High Serum Level of the Soluble CD30 Identifies Chinese Kidney Transplant Recipients at High Risk of Unfavorable Outcome [J].

Iv, R. ;

He, Q. ;

Wang, H. P. ;

Jin, J. ;

Chen, Y. ;

Chen, J. H. .

TRANSPLANTATION PROCEEDINGS, 2008, 40 (10) :3375-3380

[9] Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients [J].

Kim, In-Wha ;

Moon, Yoo Jin ;

Ji, Eunhee ;

Kim, Kyung Im ;

Han, Nayoung ;

Kim, Sung Ju ;

Shin, Wan Gyoon ;

Ha, Jongwon ;

Yoon, Jeong-Hyun ;

Lee, Hye Suk ;

Oh, Jung Mi .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (05) :657-669

[10] A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype [J].

MacPhee, Iain A. M. ;

Holt, David W. .

TRANSPLANTATION, 2008, 85 (02) :163-165

← 1 2 →